Prosecution Insights
Last updated: April 19, 2026
Application No. 18/548,766

BETA-LACTOMASE INHIBITORS AND USES THEREOF

Final Rejection §102
Filed
Sep 01, 2023
Examiner
CHICKS, ASHLI ARIANA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Universita' degil Syudi di Modena e Reggio Emilia
OA Round
2 (Final)
65%
Grant Probability
Favorable
3-4
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allow Rate
49 granted / 75 resolved
+5.3% vs TC avg
Strong +44% interview lift
Without
With
+43.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
37 currently pending
Career history
112
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
29.9%
-10.1% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 75 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1-16 and 31-34 are pending. Claims 1-16 and 32 are rejected. Claims 31 and 33-34 are objected to. Response to Amendment/Arguments Applicant’s amendments have overcome the previously presented rejections. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-16 and 32 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by WO2016050359A1 by Klein et al. The prior art discloses the following compound which reads on instant claims 1-16 and 32 (page 83, Example 2): PNG media_image1.png 138 230 media_image1.png Greyscale . The prior art compound is embraced by instant formula (I) and (II) where Z is CH2-6-membered aryl, X is alkylene, Y is -W-R2, W is O, and R2 is PNG media_image2.png 88 96 media_image2.png Greyscale . Regarding instant claims 2-3 and 11-12 which recite further limitations for R1 and claims 7 and 15 which recite further limitations for R3, the prior art compound is anticipatory because the claims do not require R1 or R3 to be present within the structure. Regarding instant claims 8 and 16, Z is PNG media_image3.png 138 172 media_image3.png Greyscale where each R3 is absent. Allowable Subject Matter Claims 31 and 33-34 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ASHLI A CHICKS whose telephone number is (571)270-0582. The examiner can normally be reached M-Th 7 a.m.- 5 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at (571)272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.A.C./Examiner, Art Unit 1626 /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Sep 01, 2023
Application Filed
Nov 28, 2025
Non-Final Rejection — §102
Feb 26, 2026
Response Filed
Mar 17, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589107
COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE AND MOGROSIDE, AND APPLICATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12590088
JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12564552
ORAL PRODUCT WITH A BASIC AMINE AND AN ION PAIRING AGENT
2y 5m to grant Granted Mar 03, 2026
Patent 12552801
NEW INDAZOLE DERIVATIVES
2y 5m to grant Granted Feb 17, 2026
Patent 12540130
SUBSTITUTED PYRROLIDINE AMIDES IV
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+43.9%)
3y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 75 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month